社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
fann
IP属地:未知
+关注
帖子 · 45
帖子 · 45
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
fann
fann
·
2021-11-28
v
非常抱歉,此主贴已删除
看
3,257
回复
评论
点赞
2
编组 21备份 2
分享
举报
fann
fann
·
2021-11-24
yes
XPeng shares rose nearly 12% in early trading<blockquote>小鹏汽车股价早盘涨近12%</blockquote>
XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported
XPeng shares rose nearly 12% in early trading<blockquote>小鹏汽车股价早盘涨近12%</blockquote>
看
1,713
回复
评论
点赞
5
编组 21备份 2
分享
举报
fann
fann
·
2021-11-13
d
Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>
Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo
Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>
看
1,989
回复
评论
点赞
5
编组 21备份 2
分享
举报
fann
fann
·
2021-11-10
h
非常抱歉,此主贴已删除
看
1,796
回复
评论
点赞
4
编组 21备份 2
分享
举报
fann
fann
·
2021-09-26
ss
Intel Starts Construction of Two Arizona Computer Chip Factories<blockquote>英特尔开始建设亚利桑那州两家计算机芯片工厂</blockquote>
Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to
Intel Starts Construction of Two Arizona Computer Chip Factories<blockquote>英特尔开始建设亚利桑那州两家计算机芯片工厂</blockquote>
看
1,558
回复
1
点赞
6
编组 21备份 2
分享
举报
fann
fann
·
2021-09-24
s
EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data<blockquote>由于缺乏安全数据,欧盟将等待决定辉瑞加强剂</blockquote>
In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing
EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data<blockquote>由于缺乏安全数据,欧盟将等待决定辉瑞加强剂</blockquote>
看
3,362
回复
评论
点赞
5
编组 21备份 2
分享
举报
fann
fann
·
2021-09-21
h
Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back<blockquote>随着全球股市反弹,道琼斯、纳斯达克、标普500期货上涨</blockquote>
The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again t
Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back<blockquote>随着全球股市反弹,道琼斯、纳斯达克、标普500期货上涨</blockquote>
看
1,519
回复
2
点赞
3
编组 21备份 2
分享
举报
fann
fann
·
2021-09-21
d
非常抱歉,此主贴已删除
看
2,717
回复
1
点赞
2
编组 21备份 2
分享
举报
fann
fann
·
2021-09-16
b
非常抱歉,此主贴已删除
看
2,570
回复
评论
点赞
1
编组 21备份 2
分享
举报
fann
fann
·
2021-09-13
f
非常抱歉,此主贴已删除
看
2,568
回复
1
点赞
4
编组 21备份 2
分享
举报
加载更多
暂无关注
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3585997214465926","uuid":"3585997214465926","gmtCreate":1622903189881,"gmtModify":1627956052914,"name":"fann","pinyin":"fann","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":12,"headSize":126,"tweetSize":45,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":600939962,"gmtCreate":1638029748530,"gmtModify":1638029748620,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"htmlText":"v","listText":"v","text":"v","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600939962","repostId":"2186389343","repostType":4,"isVote":1,"tweetType":1,"viewCount":3257,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875729976,"gmtCreate":1637697368889,"gmtModify":1637697369016,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875729976","repostId":"1117658681","repostType":4,"repost":{"id":"1117658681","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637681053,"share":"https://www.laohu8.com/m/news/1117658681?lang=zh_CN&edition=full","pubTime":"2021-11-23 23:24","market":"us","language":"en","title":"XPeng shares rose nearly 12% in early trading<blockquote>小鹏汽车股价早盘涨近12%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1117658681","media":"Tiger Newspress","summary":"XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported ","content":"<p>XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.<img src=\"https://static.tigerbbs.com/a8d43127b29dfc54fadaa9e23939d911\" tg-width=\"878\" tg-height=\"596\" referrerpolicy=\"no-referrer\">The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.</p><p><blockquote>小鹏汽车股价早盘上涨近12%,此前这家中国电动汽车制造商公布第三季度亏损超出预期,但营收远高于预期,并提供了乐观的第四季度前景。净亏损从一年前的亏损11.5亿元人民币扩大至15.9亿元人民币(2.497亿美元),即每股美国存托股票(ADS)1.89元人民币。不包括非经常性项目,调整后每股美国存托凭证亏损为人民币1.77元,而FactSet共识为人民币1.30元。</blockquote></p><p> Revenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.</p><p><blockquote>收入增长187.4%,达到人民币57.2亿元(8.955亿美元),超过FactSet预期的人民币50.3亿元,交付量增长199.2%,达到创纪录的25,666辆,其中P7车型交付量增长217.7%。</blockquote></p><p> Gross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.</p><p><blockquote>毛利率从4.6%提高至14.4%。展望未来,该公司预计第四季度交付量将在34,500辆至36,500辆之间,增长166.1%至181.5%,收入将在人民币71亿元至人民币75亿元之间,而FactSet共识为人民币60.9亿元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng shares rose nearly 12% in early trading<blockquote>小鹏汽车股价早盘涨近12%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng shares rose nearly 12% in early trading<blockquote>小鹏汽车股价早盘涨近12%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-23 23:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.<img src=\"https://static.tigerbbs.com/a8d43127b29dfc54fadaa9e23939d911\" tg-width=\"878\" tg-height=\"596\" referrerpolicy=\"no-referrer\">The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.</p><p><blockquote>小鹏汽车股价早盘上涨近12%,此前这家中国电动汽车制造商公布第三季度亏损超出预期,但营收远高于预期,并提供了乐观的第四季度前景。净亏损从一年前的亏损11.5亿元人民币扩大至15.9亿元人民币(2.497亿美元),即每股美国存托股票(ADS)1.89元人民币。不包括非经常性项目,调整后每股美国存托凭证亏损为人民币1.77元,而FactSet共识为人民币1.30元。</blockquote></p><p> Revenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.</p><p><blockquote>收入增长187.4%,达到人民币57.2亿元(8.955亿美元),超过FactSet预期的人民币50.3亿元,交付量增长199.2%,达到创纪录的25,666辆,其中P7车型交付量增长217.7%。</blockquote></p><p> Gross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.</p><p><blockquote>毛利率从4.6%提高至14.4%。展望未来,该公司预计第四季度交付量将在34,500辆至36,500辆之间,增长166.1%至181.5%,收入将在人民币71亿元至人民币75亿元之间,而FactSet共识为人民币60.9亿元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09868":"小鹏汽车-W","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117658681","content_text":"XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.\nRevenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.\nGross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.","news_type":1,"symbols_score_info":{"09868":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":1713,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873030150,"gmtCreate":1636789657540,"gmtModify":1636789657680,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"htmlText":"d","listText":"d","text":"d","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873030150","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上,辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时,听起来很头晕。就在几天前,他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说:“你能够打破这种类型的世界纪录,同时偶然获得大满贯,这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利:在短短10个月内开发出了一种效果惊人的Covid-19疫苗,一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前,辉瑞(股票代码:PFE)首席执行官阿尔伯特·布尔拉(Albert Bourla)要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品,留下了一家纯粹的生物制药公司,该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中,<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而,随着对全球疫苗分配不平等的批评越来越多,继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中,低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家,该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).</p><p><blockquote>数据公布当天,辉瑞股价飙升10.9%,创下至少20年来的最佳单日表现。尽管如此,由于该股目前易手价格约为50美元,投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍,低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的,但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上,但对于长期投资者来说,这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室,但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期,辉瑞公司将其努力分为与BioNTech在疫苗上的合作和对新冠肺炎药丸的探索。疫苗工作规模巨大;多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队,拥有相当适中的资源,”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目,其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&D is better than people had thought.”</p><p><blockquote>“(辉瑞的)制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而,辉瑞文库中的蛋白酶抑制剂已经静脉内施用,并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药,这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应,”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物,这个过程通常可能需要数年时间,但他们在几个月内就完成了。“在这里,四年变成了四个月,”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验,包括一项针对高风险患者,一项针对非高风险患者,以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中,该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示:“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级,目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示,在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前,她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级,”她说。“在这些事情发生之前,我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时,Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望,呼吁该公司提高产量,以便能够以非营利价格向低收入国家提供更多剂量,一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续,辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候,辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平,告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗,捐赠给贫穷国家,并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面,辉瑞仅表示将为较贫穷国家提供分级定价,与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议,允许其药丸在全球范围内获得许可,无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示,辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择,”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底,活动人士在布尔拉家外抗议,呼吁辉瑞分享其疫苗制造技术,并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评,使辉瑞公司相对受到华盛顿的青睐,并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上,辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时,听起来很头晕。就在几天前,他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说:“你能够打破这种类型的世界纪录,同时偶然获得大满贯,这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利:在短短10个月内开发出了一种效果惊人的Covid-19疫苗,一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前,辉瑞(股票代码:PFE)首席执行官阿尔伯特·布尔拉(Albert Bourla)要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品,留下了一家纯粹的生物制药公司,该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中,<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而,随着对全球疫苗分配不平等的批评越来越多,继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中,低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家,该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).</p><p><blockquote>数据公布当天,辉瑞股价飙升10.9%,创下至少20年来的最佳单日表现。尽管如此,由于该股目前易手价格约为50美元,投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍,低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的,但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上,但对于长期投资者来说,这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室,但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期,辉瑞公司将其努力分为与BioNTech在疫苗上的合作和对新冠肺炎药丸的探索。疫苗工作规模巨大;多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队,拥有相当适中的资源,”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目,其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&D is better than people had thought.”</p><p><blockquote>“(辉瑞的)制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而,辉瑞文库中的蛋白酶抑制剂已经静脉内施用,并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药,这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应,”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物,这个过程通常可能需要数年时间,但他们在几个月内就完成了。“在这里,四年变成了四个月,”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验,包括一项针对高风险患者,一项针对非高风险患者,以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中,该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示:“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级,目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示,在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前,她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级,”她说。“在这些事情发生之前,我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时,Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望,呼吁该公司提高产量,以便能够以非营利价格向低收入国家提供更多剂量,一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续,辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候,辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平,告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗,捐赠给贫穷国家,并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面,辉瑞仅表示将为较贫穷国家提供分级定价,与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议,允许其药丸在全球范围内获得许可,无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示,辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择,”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底,活动人士在布尔拉家外抗议,呼吁辉瑞分享其疫苗制造技术,并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评,使辉瑞公司相对受到华盛顿的青睐,并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1989,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847285132,"gmtCreate":1636524401929,"gmtModify":1636524758936,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"htmlText":"h","listText":"h","text":"h","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847285132","repostId":"1188205095","repostType":4,"isVote":1,"tweetType":1,"viewCount":1796,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868517299,"gmtCreate":1632671469211,"gmtModify":1632798663240,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"htmlText":"ss","listText":"ss","text":"ss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/868517299","repostId":"1142057327","repostType":4,"repost":{"id":"1142057327","kind":"news","pubTimestamp":1632643246,"share":"https://www.laohu8.com/m/news/1142057327?lang=zh_CN&edition=full","pubTime":"2021-09-26 16:00","market":"us","language":"en","title":"Intel Starts Construction of Two Arizona Computer Chip Factories<blockquote>英特尔开始建设亚利桑那州两家计算机芯片工厂</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1142057327","media":"The street","summary":"Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to","content":"<p>Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.</p><p><blockquote>英特尔在亚利桑那州的两家新计算机芯片工厂破土动工,这是一项200亿美元项目的一部分,旨在帮助满足美国对半导体的高需求。</blockquote></p><p> Intel (<b>INTC</b>) -Get Intel Corporation (INTC) Report on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help alleviate the severe shortage of semiconductors in the U.S.</p><p><blockquote>英特尔(<b>INTC</b>)-获取英特尔公司(INTC)报告周五在亚利桑那州的两家新计算机芯片工厂破土动工,这是一项耗资200亿美元的项目的一部分,旨在帮助缓解美国半导体的严重短缺。</blockquote></p><p> The Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.</p><p><blockquote>这家总部位于加利福尼亚州圣克拉拉的半导体芯片制造商首席执行官帕特·基辛格(Pat Gelsinger)在该公司位于亚利桑那州钱德勒的奥科蒂洛园区主持了该项目的奠基仪式,标志着该州历史上最大的私人投资。</blockquote></p><p> Intel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.</p><p><blockquote>英特尔预计这些工厂将于2024年全面投入运营,生产该公司最先进的工艺技术。</blockquote></p><p> “Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.</p><p><blockquote>基辛格在公司声明中表示:“今天的庆祝活动标志着一个重要的里程碑,因为我们正在努力提高产能并满足对半导体的难以置信的需求:半导体是万物数字化的基础技术。我们正在开创一个创新的新时代——对英特尔、对亚利桑那州和对全世界都是如此。自40多年前开业以来,这项200亿美元的扩建将使我们在亚利桑那州的总投资超过500亿美元。”</blockquote></p><p> \"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.</p><p><blockquote>Gelsinger表示:“作为唯一一家总部位于美国的领先芯片制造商,我们致力于在这项长期投资的基础上再接再厉,帮助美国重新获得半导体领先地位。”</blockquote></p><p> Shares of Intel on Friday traded 0.18% higher to $54.32 after hours.</p><p><blockquote>周五盘后英特尔股价上涨0.18%,至54.32美元。</blockquote></p><p> Gelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.</p><p><blockquote>基辛格周四参加了与科技公司高管和商务部长吉娜·雷蒙多的虚拟会议,以解决全球半导体芯片短缺问题,该问题干扰了高科技、电子和汽车行业的生产。</blockquote></p><p> The two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.</p><p><blockquote>这两个新工厂将被命名为Fab 52和Fab 62,将容纳总共六个半导体晶圆厂。该项目将创造3,000多个高科技、高工资的英特尔工作岗位、3,000个建筑工作岗位,并为当地社区提供约15,000个额外的间接工作岗位。</blockquote></p><p> Intel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.</p><p><blockquote>英特尔的竞争对手台积电公司计划也在亚利桑那州建造其在美国的第二家芯片工厂,目标是2024年开始生产。</blockquote></p><p></p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Starts Construction of Two Arizona Computer Chip Factories<blockquote>英特尔开始建设亚利桑那州两家计算机芯片工厂</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Starts Construction of Two Arizona Computer Chip Factories<blockquote>英特尔开始建设亚利桑那州两家计算机芯片工厂</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The street</strong><span class=\"h-time small\">2021-09-26 16:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.</p><p><blockquote>英特尔在亚利桑那州的两家新计算机芯片工厂破土动工,这是一项200亿美元项目的一部分,旨在帮助满足美国对半导体的高需求。</blockquote></p><p> Intel (<b>INTC</b>) -Get Intel Corporation (INTC) Report on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help alleviate the severe shortage of semiconductors in the U.S.</p><p><blockquote>英特尔(<b>INTC</b>)-获取英特尔公司(INTC)报告周五在亚利桑那州的两家新计算机芯片工厂破土动工,这是一项耗资200亿美元的项目的一部分,旨在帮助缓解美国半导体的严重短缺。</blockquote></p><p> The Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.</p><p><blockquote>这家总部位于加利福尼亚州圣克拉拉的半导体芯片制造商首席执行官帕特·基辛格(Pat Gelsinger)在该公司位于亚利桑那州钱德勒的奥科蒂洛园区主持了该项目的奠基仪式,标志着该州历史上最大的私人投资。</blockquote></p><p> Intel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.</p><p><blockquote>英特尔预计这些工厂将于2024年全面投入运营,生产该公司最先进的工艺技术。</blockquote></p><p> “Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.</p><p><blockquote>基辛格在公司声明中表示:“今天的庆祝活动标志着一个重要的里程碑,因为我们正在努力提高产能并满足对半导体的难以置信的需求:半导体是万物数字化的基础技术。我们正在开创一个创新的新时代——对英特尔、对亚利桑那州和对全世界都是如此。自40多年前开业以来,这项200亿美元的扩建将使我们在亚利桑那州的总投资超过500亿美元。”</blockquote></p><p> \"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.</p><p><blockquote>Gelsinger表示:“作为唯一一家总部位于美国的领先芯片制造商,我们致力于在这项长期投资的基础上再接再厉,帮助美国重新获得半导体领先地位。”</blockquote></p><p> Shares of Intel on Friday traded 0.18% higher to $54.32 after hours.</p><p><blockquote>周五盘后英特尔股价上涨0.18%,至54.32美元。</blockquote></p><p> Gelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.</p><p><blockquote>基辛格周四参加了与科技公司高管和商务部长吉娜·雷蒙多的虚拟会议,以解决全球半导体芯片短缺问题,该问题干扰了高科技、电子和汽车行业的生产。</blockquote></p><p> The two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.</p><p><blockquote>这两个新工厂将被命名为Fab 52和Fab 62,将容纳总共六个半导体晶圆厂。该项目将创造3,000多个高科技、高工资的英特尔工作岗位、3,000个建筑工作岗位,并为当地社区提供约15,000个额外的间接工作岗位。</blockquote></p><p> Intel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.</p><p><blockquote>英特尔的竞争对手台积电公司计划也在亚利桑那州建造其在美国的第二家芯片工厂,目标是2024年开始生产。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories\">The street</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"source_url":"https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142057327","content_text":"Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.\nIntel (INTC) -Get Intel Corporation (INTC) Report on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help alleviate the severe shortage of semiconductors in the U.S.\nThe Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.\nIntel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.\n“Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.\n\"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.\nShares of Intel on Friday traded 0.18% higher to $54.32 after hours.\nGelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.\nThe two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.\nIntel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.","news_type":1,"symbols_score_info":{"INTC":0.9}},"isVote":1,"tweetType":1,"viewCount":1558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861838061,"gmtCreate":1632479579653,"gmtModify":1632719680697,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"htmlText":"s","listText":"s","text":"s","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861838061","repostId":"1147407851","repostType":4,"repost":{"id":"1147407851","kind":"news","pubTimestamp":1632476902,"share":"https://www.laohu8.com/m/news/1147407851?lang=zh_CN&edition=full","pubTime":"2021-09-24 17:48","market":"us","language":"en","title":"EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data<blockquote>由于缺乏安全数据,欧盟将等待决定辉瑞加强剂</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1147407851","media":"zerohedge","summary":"In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing","content":"<p>In keeping with their more cautious approach toward approving COVID jabs,<b>EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jab</b>s - but not until early October,Reuters reportedThursday.</p><p><blockquote>为了与他们在批准新冠疫苗接种方面采取更加谨慎的态度保持一致,<b>欧盟监管机构正准备自行决定是否批准辉瑞疫苗的加强注射</b>但据路透社周四报道,直到十月初。</blockquote></p><p> Reuters pointed out that<b>the upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabs</b>in the EU.</p><p><blockquote>路透社指出,<b>即将对辉瑞加强疫苗进行的审查将标志着欧洲监管机构首次决定发放加强疫苗</b>在欧盟。</blockquote></p><p> In an opinion issued earlier this month that was republished by the EMA,<b>the European Center for Disease Prevention and Control</b>- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -<b>said there was no \"urgent need\" to administer booster doses</b>to fully vaccinated individuals in the general population.</p><p><blockquote>在本月早些时候发布并由EMA重新发布的意见中,<b>欧洲疾病预防和控制中心</b>-或ECDC,组成欧盟最高级别卫生监管机构的几个监管机构之一-<b>称没有“迫切需要”注射加强剂量</b>普通人群中完全接种疫苗的个体。</blockquote></p><p> But it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever</p><p><blockquote>但它也指出,额外的剂量已经在考虑中,并分发给老年人、免疫功能低下的人等</blockquote></p><p> Regardless of whatever the bloc decides,<b>it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.</b></p><p><blockquote>不管欧盟做出什么决定,<b>该公司最近已与辉瑞(Pfizer)和BioNTech签署了再注射24亿支mRNA疫苗的协议。</b></blockquote></p><p> The latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.</p><p><blockquote>最新的合同涵盖了至少900毫米的疫苗供应,只有在欧盟继续实施广泛的加强注射计划并向所有16岁及以上的成年人提供疫苗的情况下,才需要这些疫苗。。超过70%的欧盟成年人已经完全接种了疫苗,欧盟已经从几家制造商那里获得了充足的疫苗供应。</blockquote></p><p> Still, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.</p><p><blockquote>尽管如此,随着delta波继续给世界各地的政治家带来问题,他们可能会越来越不顾一切地强迫人们接种3、4甚至5针——尽管ECDC表示,关于加强剂的需求和安全性的关键数据尚未从世界各地展开的研究中收集,部分原因是还不完全清楚疫苗对病毒的保护作用有多长时间。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data<blockquote>由于缺乏安全数据,欧盟将等待决定辉瑞加强剂</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data<blockquote>由于缺乏安全数据,欧盟将等待决定辉瑞加强剂</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">zerohedge</strong><span class=\"h-time small\">2021-09-24 17:48</span>\n</p>\n</h4>\n</header>\n<article>\n<p>In keeping with their more cautious approach toward approving COVID jabs,<b>EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jab</b>s - but not until early October,Reuters reportedThursday.</p><p><blockquote>为了与他们在批准新冠疫苗接种方面采取更加谨慎的态度保持一致,<b>欧盟监管机构正准备自行决定是否批准辉瑞疫苗的加强注射</b>但据路透社周四报道,直到十月初。</blockquote></p><p> Reuters pointed out that<b>the upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabs</b>in the EU.</p><p><blockquote>路透社指出,<b>即将对辉瑞加强疫苗进行的审查将标志着欧洲监管机构首次决定发放加强疫苗</b>在欧盟。</blockquote></p><p> In an opinion issued earlier this month that was republished by the EMA,<b>the European Center for Disease Prevention and Control</b>- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -<b>said there was no \"urgent need\" to administer booster doses</b>to fully vaccinated individuals in the general population.</p><p><blockquote>在本月早些时候发布并由EMA重新发布的意见中,<b>欧洲疾病预防和控制中心</b>-或ECDC,组成欧盟最高级别卫生监管机构的几个监管机构之一-<b>称没有“迫切需要”注射加强剂量</b>普通人群中完全接种疫苗的个体。</blockquote></p><p> But it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever</p><p><blockquote>但它也指出,额外的剂量已经在考虑中,并分发给老年人、免疫功能低下的人等</blockquote></p><p> Regardless of whatever the bloc decides,<b>it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.</b></p><p><blockquote>不管欧盟做出什么决定,<b>该公司最近已与辉瑞(Pfizer)和BioNTech签署了再注射24亿支mRNA疫苗的协议。</b></blockquote></p><p> The latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.</p><p><blockquote>最新的合同涵盖了至少900毫米的疫苗供应,只有在欧盟继续实施广泛的加强注射计划并向所有16岁及以上的成年人提供疫苗的情况下,才需要这些疫苗。。超过70%的欧盟成年人已经完全接种了疫苗,欧盟已经从几家制造商那里获得了充足的疫苗供应。</blockquote></p><p> Still, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.</p><p><blockquote>尽管如此,随着delta波继续给世界各地的政治家带来问题,他们可能会越来越不顾一切地强迫人们接种3、4甚至5针——尽管ECDC表示,关于加强剂的需求和安全性的关键数据尚未从世界各地展开的研究中收集,部分原因是还不完全清楚疫苗对病毒的保护作用有多长时间。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">zerohedge</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147407851","content_text":"In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jabs - but not until early October,Reuters reportedThursday.\nReuters pointed out thatthe upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabsin the EU.\nIn an opinion issued earlier this month that was republished by the EMA,the European Center for Disease Prevention and Control- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -said there was no \"urgent need\" to administer booster dosesto fully vaccinated individuals in the general population.\nBut it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever\nRegardless of whatever the bloc decides,it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.\nThe latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.\nStill, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":860763767,"gmtCreate":1632214972359,"gmtModify":1632802025039,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"htmlText":"h","listText":"h","text":"h","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/860763767","repostId":"1138597781","repostType":4,"repost":{"id":"1138597781","kind":"news","pubTimestamp":1632214755,"share":"https://www.laohu8.com/m/news/1138597781?lang=zh_CN&edition=full","pubTime":"2021-09-21 16:59","market":"us","language":"en","title":"Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back<blockquote>随着全球股市反弹,道琼斯、纳斯达克、标普500期货上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138597781","media":"seekingalpha","summary":"The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again t","content":"<p>The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again today, pushing stocks higher around the world.</p><p><blockquote>昨天在华尔街交易最后一个小时介入的逢低买家今天再次回归,推动全球股市走高。</blockquote></p><p> S&P futures(SPX), Nasdaq 100 futures(NDX:IND)and Dow Jones futures(INDU)are all up about 1%.</p><p><blockquote>标准普尔期货(SPX)、纳斯达克100期货(NDX:IND)和道琼斯期货(INDU)均上涨约1%。</blockquote></p><p> In Asia, Japan's Nikkei(NKY:IND)is lower, catching up with trading after a holiday on Monday, but Hong Kong's Hang Seng(HSI)is up more than half a percent.</p><p><blockquote>在亚洲,日本日经指数(NKY:IND)走低,赶上周一假期后的交易,但香港恒生指数(HSI)上涨超过0.5%。</blockquote></p><p> In Europe, the benchmark indexes in Frankfurt, London and Paris are more than 1% higher, with the broader Stoxx 600(STOXX)up 1%.</p><p><blockquote>在欧洲,法兰克福、伦敦和巴黎的基准指数上涨超过1%,斯托克600指数(STOXX)上涨1%。</blockquote></p><p> Rates are paring losses, with the 10-year Treasury yield(NYSEARCA:TBT)(NASDAQ:TLT)up 3 basis points to 1.34%.</p><p><blockquote>利率正在缩小损失,10年期国债收益率(NYSEARCA:TBT)(纳斯达克:TLT)上涨3个基点至1.34%。</blockquote></p><p> And volatility is ebbing. The S&P Vix Index(VIX), also referred to as the fear gauge, is down 12% after a surge yesterday.</p><p><blockquote>波动性正在减弱。标准普尔VIX指数(VIX),也被称为恐惧指标,在昨天飙升后下跌12%。</blockquote></p><p> The VIX \"traded north of 25 for the first time since May, a rise which is likely to have exacerbated some of the declines, with risk models forcing positions to be trimmed as volatility climbs, thus increasing selling, fueling a further increase in volatility; and so on, and so forth,\" Michael Brown, senior market analyst at Caxton writes.</p><p><blockquote>VIX“自5月份以来首次突破25,这一上涨可能加剧了部分下跌,随着波动性攀升,风险模型迫使头寸削减,从而增加抛售,推动波动性进一步增加;等等,”卡克斯顿高级市场分析师迈克·布朗写道。</blockquote></p><p> <b>No Lehman moment.</b>Jitters about the impact of China's Evergrande defaulting on interest payments have eased overnight.</p><p><blockquote><b>没有雷曼时刻。</b>关于中国恒大拖欠利息支付影响的不安情绪一夜之间有所缓解。</blockquote></p><p> S&P Global Ratings says that a governmentbailout is unlikely unless there is systemic risk and \"far-reaching\" contagion from Evergrande.</p><p><blockquote>标准普尔全球评级表示,除非恒大出现系统性风险和“深远”蔓延,否则政府不太可能实施救助。</blockquote></p><p> But the S&P analysts also say the property company \"failing alone would unlikely result in such a scenario.\"</p><p><blockquote>但标准普尔分析师也表示,这家房地产公司“单独失败不太可能导致这种情况”。</blockquote></p><p> \"The crisis at Evergrande and in the Chinese real estate sector was the catalyst (for a selloff) most people were talking about, but truth be told, the market rout we’re seeing is reflecting a wider set of risks than just Chinese property, and comes after increasing questions have been asked about whether current valuations could still be justified, with talk of a potential correction picking up,\" Deutsche Bank strategist Jim Reid writes today.</p><p><blockquote>“恒大和中国房地产行业的危机是大多数人都在谈论的(抛售)催化剂,但说实话,我们看到的市场暴跌反映了更广泛的风险,而不仅仅是中国房地产,德意志银行策略师吉姆·里德今天写道:“在越来越多的人质疑当前估值是否仍然合理之后,有关潜在调整的讨论也在增加。”</blockquote></p><p> \"Remember that 68% of respondents to my survey last week thought they’d be at least a 5% correction in equity markets before year end. So this has been front and center of people’s mind even if the catalyst hasn’t been clear,\" he adds.</p><p><blockquote>“请记住,我上周调查的68%的受访者认为年底前股市至少会出现5%的调整。因此,即使催化剂尚不清楚,这也一直是人们关注的焦点,”他补充道。</blockquote></p><p> <b>Time to buy?</b>Monday's tumble brought some bullish calls from Wall Street banks, where several strategists still see the path of the broader market moving up and to the right.</p><p><blockquote><b>是时候买了?</b>周一的暴跌带来了华尔街银行的一些看涨评级,几位策略师仍然认为大盘将向上和向右移动。</blockquote></p><p> \"The market sell-off that escalated overnight we believe is primarily driven by technical selling flows (CTAs and option hedgers) in an environment of poor liquidity, and overreaction of discretionary traders to perceived risks,” Marko Kolanovic, chief global market strategist at JPMorgan, wrote in a note yesterday. “Our fundamental thesis remains unchanged, and we see the sell-off as an opportunity to buy the dip.”</p><p><blockquote>摩根大通首席全球市场策略师Marko Kolanovic昨天在一份报告中写道:“我们认为,隔夜升级的市场抛售主要是由流动性不佳的环境下的技术性抛售流(CTA和期权对冲者)以及全权交易者对感知风险的过度反应推动的。”</blockquote></p><p> From a technical perspective, Piper Sandler strategist Craig W. Johnson called this week a \"key test for the buy the dip crowd\" and that a failure to defend the S&P's 50-day moving average around 4,436 \"would suggest the broader market is at risk for a deeper pullback.\"</p><p><blockquote>从技术角度来看,Piper Sandler策略师克雷格·W·约翰逊(Craig W.Johnson)称本周是“对逢低买入人群的关键考验”,如果未能守住标普指数4,436点附近的50日移动平均线,“将表明大盘面临更深回调的风险。”</blockquote></p><p> But Thomas Lee, head of research at Fundstrat, agreed with Kolanovic, saying on CNBC the time was right to look at adding to positions.</p><p><blockquote>但Fundstrat研究主管Thomas Lee同意Kolanovic的观点,他在CNBC上表示,现在是考虑增加头寸的时候了。</blockquote></p><p> \"I would look at selloffs like this, which is sort of broad-based selling, as a time to add incrementally,\"Lee said.</p><p><blockquote>“我认为像这样的抛售,这是一种广泛的抛售,是逐步增加的时候,”李说。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back<blockquote>随着全球股市反弹,道琼斯、纳斯达克、标普500期货上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back<blockquote>随着全球股市反弹,道琼斯、纳斯达克、标普500期货上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-09-21 16:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again today, pushing stocks higher around the world.</p><p><blockquote>昨天在华尔街交易最后一个小时介入的逢低买家今天再次回归,推动全球股市走高。</blockquote></p><p> S&P futures(SPX), Nasdaq 100 futures(NDX:IND)and Dow Jones futures(INDU)are all up about 1%.</p><p><blockquote>标准普尔期货(SPX)、纳斯达克100期货(NDX:IND)和道琼斯期货(INDU)均上涨约1%。</blockquote></p><p> In Asia, Japan's Nikkei(NKY:IND)is lower, catching up with trading after a holiday on Monday, but Hong Kong's Hang Seng(HSI)is up more than half a percent.</p><p><blockquote>在亚洲,日本日经指数(NKY:IND)走低,赶上周一假期后的交易,但香港恒生指数(HSI)上涨超过0.5%。</blockquote></p><p> In Europe, the benchmark indexes in Frankfurt, London and Paris are more than 1% higher, with the broader Stoxx 600(STOXX)up 1%.</p><p><blockquote>在欧洲,法兰克福、伦敦和巴黎的基准指数上涨超过1%,斯托克600指数(STOXX)上涨1%。</blockquote></p><p> Rates are paring losses, with the 10-year Treasury yield(NYSEARCA:TBT)(NASDAQ:TLT)up 3 basis points to 1.34%.</p><p><blockquote>利率正在缩小损失,10年期国债收益率(NYSEARCA:TBT)(纳斯达克:TLT)上涨3个基点至1.34%。</blockquote></p><p> And volatility is ebbing. The S&P Vix Index(VIX), also referred to as the fear gauge, is down 12% after a surge yesterday.</p><p><blockquote>波动性正在减弱。标准普尔VIX指数(VIX),也被称为恐惧指标,在昨天飙升后下跌12%。</blockquote></p><p> The VIX \"traded north of 25 for the first time since May, a rise which is likely to have exacerbated some of the declines, with risk models forcing positions to be trimmed as volatility climbs, thus increasing selling, fueling a further increase in volatility; and so on, and so forth,\" Michael Brown, senior market analyst at Caxton writes.</p><p><blockquote>VIX“自5月份以来首次突破25,这一上涨可能加剧了部分下跌,随着波动性攀升,风险模型迫使头寸削减,从而增加抛售,推动波动性进一步增加;等等,”卡克斯顿高级市场分析师迈克·布朗写道。</blockquote></p><p> <b>No Lehman moment.</b>Jitters about the impact of China's Evergrande defaulting on interest payments have eased overnight.</p><p><blockquote><b>没有雷曼时刻。</b>关于中国恒大拖欠利息支付影响的不安情绪一夜之间有所缓解。</blockquote></p><p> S&P Global Ratings says that a governmentbailout is unlikely unless there is systemic risk and \"far-reaching\" contagion from Evergrande.</p><p><blockquote>标准普尔全球评级表示,除非恒大出现系统性风险和“深远”蔓延,否则政府不太可能实施救助。</blockquote></p><p> But the S&P analysts also say the property company \"failing alone would unlikely result in such a scenario.\"</p><p><blockquote>但标准普尔分析师也表示,这家房地产公司“单独失败不太可能导致这种情况”。</blockquote></p><p> \"The crisis at Evergrande and in the Chinese real estate sector was the catalyst (for a selloff) most people were talking about, but truth be told, the market rout we’re seeing is reflecting a wider set of risks than just Chinese property, and comes after increasing questions have been asked about whether current valuations could still be justified, with talk of a potential correction picking up,\" Deutsche Bank strategist Jim Reid writes today.</p><p><blockquote>“恒大和中国房地产行业的危机是大多数人都在谈论的(抛售)催化剂,但说实话,我们看到的市场暴跌反映了更广泛的风险,而不仅仅是中国房地产,德意志银行策略师吉姆·里德今天写道:“在越来越多的人质疑当前估值是否仍然合理之后,有关潜在调整的讨论也在增加。”</blockquote></p><p> \"Remember that 68% of respondents to my survey last week thought they’d be at least a 5% correction in equity markets before year end. So this has been front and center of people’s mind even if the catalyst hasn’t been clear,\" he adds.</p><p><blockquote>“请记住,我上周调查的68%的受访者认为年底前股市至少会出现5%的调整。因此,即使催化剂尚不清楚,这也一直是人们关注的焦点,”他补充道。</blockquote></p><p> <b>Time to buy?</b>Monday's tumble brought some bullish calls from Wall Street banks, where several strategists still see the path of the broader market moving up and to the right.</p><p><blockquote><b>是时候买了?</b>周一的暴跌带来了华尔街银行的一些看涨评级,几位策略师仍然认为大盘将向上和向右移动。</blockquote></p><p> \"The market sell-off that escalated overnight we believe is primarily driven by technical selling flows (CTAs and option hedgers) in an environment of poor liquidity, and overreaction of discretionary traders to perceived risks,” Marko Kolanovic, chief global market strategist at JPMorgan, wrote in a note yesterday. “Our fundamental thesis remains unchanged, and we see the sell-off as an opportunity to buy the dip.”</p><p><blockquote>摩根大通首席全球市场策略师Marko Kolanovic昨天在一份报告中写道:“我们认为,隔夜升级的市场抛售主要是由流动性不佳的环境下的技术性抛售流(CTA和期权对冲者)以及全权交易者对感知风险的过度反应推动的。”</blockquote></p><p> From a technical perspective, Piper Sandler strategist Craig W. Johnson called this week a \"key test for the buy the dip crowd\" and that a failure to defend the S&P's 50-day moving average around 4,436 \"would suggest the broader market is at risk for a deeper pullback.\"</p><p><blockquote>从技术角度来看,Piper Sandler策略师克雷格·W·约翰逊(Craig W.Johnson)称本周是“对逢低买入人群的关键考验”,如果未能守住标普指数4,436点附近的50日移动平均线,“将表明大盘面临更深回调的风险。”</blockquote></p><p> But Thomas Lee, head of research at Fundstrat, agreed with Kolanovic, saying on CNBC the time was right to look at adding to positions.</p><p><blockquote>但Fundstrat研究主管Thomas Lee同意Kolanovic的观点,他在CNBC上表示,现在是考虑增加头寸的时候了。</blockquote></p><p> \"I would look at selloffs like this, which is sort of broad-based selling, as a time to add incrementally,\"Lee said.</p><p><blockquote>“我认为像这样的抛售,这是一种广泛的抛售,是逐步增加的时候,”李说。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://seekingalpha.com/news/3741654-dow-jones-nasdaq-sp-500-futures-rally-as-global-equities-bounce-back\">seekingalpha</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://seekingalpha.com/news/3741654-dow-jones-nasdaq-sp-500-futures-rally-as-global-equities-bounce-back","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138597781","content_text":"The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again today, pushing stocks higher around the world.\nS&P futures(SPX), Nasdaq 100 futures(NDX:IND)and Dow Jones futures(INDU)are all up about 1%.\nIn Asia, Japan's Nikkei(NKY:IND)is lower, catching up with trading after a holiday on Monday, but Hong Kong's Hang Seng(HSI)is up more than half a percent.\nIn Europe, the benchmark indexes in Frankfurt, London and Paris are more than 1% higher, with the broader Stoxx 600(STOXX)up 1%.\nRates are paring losses, with the 10-year Treasury yield(NYSEARCA:TBT)(NASDAQ:TLT)up 3 basis points to 1.34%.\nAnd volatility is ebbing. The S&P Vix Index(VIX), also referred to as the fear gauge, is down 12% after a surge yesterday.\nThe VIX \"traded north of 25 for the first time since May, a rise which is likely to have exacerbated some of the declines, with risk models forcing positions to be trimmed as volatility climbs, thus increasing selling, fueling a further increase in volatility; and so on, and so forth,\" Michael Brown, senior market analyst at Caxton writes.\nNo Lehman moment.Jitters about the impact of China's Evergrande defaulting on interest payments have eased overnight.\nS&P Global Ratings says that a governmentbailout is unlikely unless there is systemic risk and \"far-reaching\" contagion from Evergrande.\nBut the S&P analysts also say the property company \"failing alone would unlikely result in such a scenario.\"\n\"The crisis at Evergrande and in the Chinese real estate sector was the catalyst (for a selloff) most people were talking about, but truth be told, the market rout we’re seeing is reflecting a wider set of risks than just Chinese property, and comes after increasing questions have been asked about whether current valuations could still be justified, with talk of a potential correction picking up,\" Deutsche Bank strategist Jim Reid writes today.\n\"Remember that 68% of respondents to my survey last week thought they’d be at least a 5% correction in equity markets before year end. So this has been front and center of people’s mind even if the catalyst hasn’t been clear,\" he adds.\nTime to buy?Monday's tumble brought some bullish calls from Wall Street banks, where several strategists still see the path of the broader market moving up and to the right.\n\"The market sell-off that escalated overnight we believe is primarily driven by technical selling flows (CTAs and option hedgers) in an environment of poor liquidity, and overreaction of discretionary traders to perceived risks,” Marko Kolanovic, chief global market strategist at JPMorgan, wrote in a note yesterday. “Our fundamental thesis remains unchanged, and we see the sell-off as an opportunity to buy the dip.”\nFrom a technical perspective, Piper Sandler strategist Craig W. Johnson called this week a \"key test for the buy the dip crowd\" and that a failure to defend the S&P's 50-day moving average around 4,436 \"would suggest the broader market is at risk for a deeper pullback.\"\nBut Thomas Lee, head of research at Fundstrat, agreed with Kolanovic, saying on CNBC the time was right to look at adding to positions.\n\"I would look at selloffs like this, which is sort of broad-based selling, as a time to add incrementally,\"Lee said.","news_type":1,"symbols_score_info":{".IXIC":0.9,".DJI":0.9,"SPY":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":1519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860850406,"gmtCreate":1632154329105,"gmtModify":1632802448027,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"htmlText":"d","listText":"d","text":"d","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860850406","repostId":"2168268325","repostType":4,"isVote":1,"tweetType":1,"viewCount":2717,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885654617,"gmtCreate":1631790309739,"gmtModify":1631889585555,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"htmlText":"b","listText":"b","text":"b","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885654617","repostId":"1133643403","repostType":4,"isVote":1,"tweetType":1,"viewCount":2570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886974284,"gmtCreate":1631547272448,"gmtModify":1631889585568,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"htmlText":"f","listText":"f","text":"f","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/886974284","repostId":"2166303094","repostType":4,"isVote":1,"tweetType":1,"viewCount":2568,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}